Editor-in-Chief

Dr. Cao is the principal scientist of the national key basic research program (973 program), the National Outstanding Youth Scholar, the professor for a special post of “Chang-Jiang scholar award scheme”, and the leading scientist in Oncology especially in liver cancer. Currently, Dr. Cao also chairs the water-related disaster branch of Chinese medical association of disaster rescue, serves as the vice-president of Shanghai preventive medicine society, and the editor-in-chief of international journal . Dr. Cao was graduated from the Second Military Medical University and got his PhD degree, master degree and bachelor degree of clinical medicine, respectively. After graduated, Dr. Cao received his 3.5-year post-doctoral trainings in Baylor College of Medicine and UT MD Anderson cancer center in Texas, USA. The major research interests are to elucidate the mechanisms by which cancers develop and metastasize, identify novel diagnostic, predictive, and prognostic biomarkers, as well as therapeutic targets for some malignancies. Dr. Cao is in charge of several national research projects including the key project, integrated project, key international collaborative project, and COVID-19 specific project from the national natural scientific foundation of China (NSFC). As the corresponding author, Dr. Cao published 156 papers in professional English journals with impact factors (IFs). Of those, 15 papers were published in the ones with IFs of greater than 10. For the first time, Dr. Cao originated a theory of Cancer Evo-Dev, based on his research on hepatitis B virus (HBV)-induced hepatocarcinogenesis and malignancies of other histotypes like colorectal carcinoma, renal cell carcinoma, and gastric cancer. Served as the editor-in-chief, Dr. Cao published 9 books including < Cancer Evo-Dev>. As the first winner, Dr. Cao got the National Natural Science Award of the second degree in 2019, the Natural Science Award of the first degree Department of Education in 2018, the Science and Technology Progress Award of the first degree in Shanghai in 2018, the Science and Technology Progress Award of the first degree, PLA in 1999, the Science and Technology Award of the first degree, Shanghai Medical Association in 2010. Moreover, Dr. Cao was also awarded the National Science and Technology Progress Award of the second degree in 2004 and 2011 as well as the National Science and Technology Team Award in 2012. Dr. Cao got a total of 36 Science and Technology Awards of different degree, and 13 approved patents.

hepatitis B virus, hepatocellular carcinoma, evolution, prediction, prophylaxis, therapeutic option, predicative biomarker, prognostic biomarkers